Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors
- Thursday, January 20, 2022, 7:12
- PR Newswire
- Add a comment
NEW YORK, Jan. 20, 2022 /PRNewswire/ — Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has…
About the Author
admin has written 21717 stories on this site.